文献速递慢性肾脏病

晚期慢性肾脏病老年人的国际处方模式与多重用药:EQUAL研究结果

International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本研究基于欧洲EQUAL前瞻性队列,分析5国1317例≥65岁晚期CKD患者的基线处方数据。结果显示91%存在多重用药(≥5种),43%存在超多重用药(≥10种),心血管药物最常见(人均3.5种)。超多重用药存在显著国际差异,德国、荷兰、意大利风险高于英国,波兰最低。

要点

  • 晚期CKD老年人多重用药普遍,超多重用药达43%。
  • 心血管药物是主要处方药物,人均3.5种。
  • 超多重用药存在显著国际差异,提示处方共识缺乏。

核心结论

  • 晚期CKD老年人中超多重用药常见,且处方数量存在显著国际差异,可能反映缺乏针对该高风险群体的适当处方共识。

研究设计与样本

  • EQUAL研究为国际前瞻性队列研究,纳入5个欧洲国家1317例≥65岁晚期CKD患者,分析基线人口学、临床和药物数据。

主要发现

  • 91%的参与者存在多重用药(≥5种药物),43%存在超多重用药(≥10种药物)。
  • 心血管药物是最常处方的药物,人均3.5种。
  • 与英国相比,德国超多重用药OR为2.75(95%CI 1.73-4.37;P<0.001),荷兰OR为1.91(95%CI 1.32-2.76;P=0.001),意大利OR为1.57(95%CI 1.15-2.15;P=0.004)。
  • 波兰超多重用药最少,OR为0.39(95%CI 0.17-0.87;P=0.021)。

临床怎么用

  • 对晚期CKD老年人应常规评估多重用药,尤其关注超多重用药(≥10种)。
  • 处方时需考虑国际实践差异,促进针对高风险群体的适当处方共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with chronic kidney disease (CKD) are at high risk of polypharmacy. However, no previous study has investigated international prescribing patterns in this group. This article aims to examine prescribing and polypharmacy patterns among older people with advanced CKD across the countries involved in the European Quality (EQUAL) study. METHODS: The EQUAL study is an international prospective cohort study of patients ≥65 years of age with advanced CKD. Baseline demographic, clinical and medication data were analysed and reported descriptively. Polypharmacy was defined as ≥5 medications and hyperpolypharmacy as ≥10. Univariable and multivariable linear regressions were used to determine associations between country and the number of prescribed medications. Univariable and multivariable logistic regression were used to determine associations between country and hyperpolypharmacy. RESULTS: Of the 1317 participants from five European countries, 91% were experiencing polypharmacy and 43% were experiencing hyperpolypharmacy. Cardiovascular medications were the most prescribed medications (mean 3.5 per person). There were international differences in prescribing, with significantly greater hyperpolypharmacy in Germany {odds ratio (OR) 2.75 [95% confidence interval (CI) 1.73-4.37]; P < 0.001, reference group UK}, the Netherlands [OR 1.91 (95% CI 1.32-2.76); P = 0.001] and Italy [OR 1.57 (95% CI 1.15-2.15); P = 0.004]. People in Poland experienced the least hyperpolypharmacy [OR 0.39 (95% CI 0.17-0.87); P = 0.021]. CONCLUSIONS: Hyperpolypharmacy is common among older people with advanced CKD, with significant international differences in the number of medications prescribed. Practice variation may represent a lack of consensus regarding appropriate prescribing for this high-risk group for whom pharmacological treatment has great potential for harm as well as benefit.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hayward S, Hole B, Denholm R, et al. International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study. Nephrol Dial Transplant. 2021. PMID: 32543669. doi:10.1093/ndt/gfaa064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。